Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT ID: NCT06170788
Last Updated: 2026-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
614 participants
INTERVENTIONAL
2023-12-15
2030-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968
Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC
NCT06706219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Sacituzumab tirumotecan
Participants receive sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle + 400 mg Pembrolizumab every 6 weeks (q6w) via IV infusion on Day 1 of each 6-week cycle for 18 cycles. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
Sacituzumab tirumotecan
IV infusion
Pembrolizumab
IV infusion
Supportive care measures
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Pembrolizumab
Participants receive 400 mg Pembrolizumab via IV infusion q6w on Day 1 of each 6-week cycle for 18 cycles
Pembrolizumab
IV infusion
Supportive care measures
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
IV infusion
Pembrolizumab
IV infusion
Supportive care measures
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy
* Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory
* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization.
* A life expectancy of at least 3 months.
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
Exclusion Criteria
* Has Grade ≥2 peripheral neuropathy.
* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention.
* Received prior systemic anticancer therapy for their metastatic NSCLC.
* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.
* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
* Received radiation therapy to the lung that is \>30 Gy within 6 months of start of study intervention.
* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
* Known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Known intolerance to sacituzumab tirumotecan or pembrolizumab and/or any of their excipients; for pembrolizumab, severe hypersensitivity (≥Grade 3) is exclusionary.
* Known hypersensitivity to sacituzumab tirumotecan or other biologic therapy.
* Active autoimmune disease that has required systemic treatment in the past 2 years.
* History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD.
* Active infection requiring systemic therapy
* Concurrent active Hepatitis B and Hepatitis C virus infection.
* Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* History of allogeneic tissue/solid organ transplant.
* Requires treatment with a strong inhibitor or inducer of Cytochrome P450 3A4 (CYP3A4) at least 14 days before the first dose of study intervention and throughout the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona - Phoenix ( Site 0147)
Phoenix, Arizona, United States
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130)
Burbank, California, United States
Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132)
Grand Junction, Colorado, United States
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
Jacksonville, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106)
Marietta, Georgia, United States
The University of Louisville, James Graham Brown Cancer Center ( Site 0121)
Louisville, Kentucky, United States
New England Cancer Specialists ( Site 0143)
Westbrook, Maine, United States
University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144)
Worcester, Massachusetts, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115)
Minneapolis, Minnesota, United States
Mayo Clinic - Rochester ( Site 0148)
Rochester, Minnesota, United States
Hattiesburg Clinic Hematology/Oncology ( Site 0104)
Hattiesburg, Mississippi, United States
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134)
Reno, Nevada, United States
University Hospitals Cleveland Medical Center ( Site 0119)
Cleveland, Ohio, United States
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117)
Corvallis, Oregon, United States
Oncology Consultants P.A. ( Site 0129)
Houston, Texas, United States
Instituto Alexander Fleming ( Site 0306)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Hospital Británico de Buenos Aires-Oncology ( Site 0304)
Buenos Aires, Buenos Aires F.D., Argentina
Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)
Río Cuarto, Córdoba Province, Argentina
Instituto de Oncología de Rosario ( Site 0301)
Rosario, Santa Fe Province, Argentina
Hospital Aleman-Oncology ( Site 0300)
Buenos Aires, , Argentina
Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002)
Port Macquarie, New South Wales, Australia
Westmead Hospital ( Site 3000)
Westmead, New South Wales, Australia
Grampians Health-Medical Oncology ( Site 3001)
Ballarat Central, Victoria, Australia
Northern Hospital ( Site 3003)
Epping, Victoria, Australia
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0409)
Porto Alegre, Rio Grande do Sul, Brazil
Clinica Viver ( Site 0400)
Santa Maria, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0402)
Barretos, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0406)
São José do Rio Preto, São Paulo, Brazil
Instituto Nacional de Câncer - INCA ( Site 0405)
Rio de Janeiro, , Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0401)
São Paulo, , Brazil
William Osler Health System ( Site 0203)
Brampton, Ontario, Canada
Trillium Health Partners - Credit Valley Hospital ( Site 0202)
Mississauga, Ontario, Canada
McGill University Health Centre ( Site 0200)
Montreal, Quebec, Canada
Clinica Universidad Catolica del Maule-Oncology ( Site 0501)
Talca, Maule Region, Chile
Orlandi Oncologia-Oncology ( Site 0504)
Santiago, Region M. de Santiago, Chile
FALP-UIDO ( Site 0509)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0507)
Santiago, Region M. de Santiago, Chile
Bradford Hill Norte ( Site 0516)
Antofagasta, , Chile
Second Affiliated hospital of Anhui Medical University ( Site 3133)
Hefei, Anhui, China
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 3101)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 3100)
Beijing, Beijing Municipality, China
Fujian Provincial Cancer Hospital ( Site 3131)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 3107)
Xiamen, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University ( Site 3134)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3108)
Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University ( Site 3123)
Zhanjiang, Guangdong, China
The Second Hospital of Hebei Medical University ( Site 3135)
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital-oncology of department ( Site 3132)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 3116)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 3117)
Wuhan, Hubei, China
Wuhan Union Hospital ( Site 3130)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 3106)
Wuhan, Hubei, China
Xiangyang Central Hospital-oncology department ( Site 3136)
Xiangyang, Hubei, China
The Second Xiangya Hospital of Central South University ( Site 3138)
Changsha, Hunan, China
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3113)
Wuxi, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College ( Site 3112)
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 3127)
Nanchang, Jiangxi, China
The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 3121)
Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital ( Site 3143)
Nanchang, Jiangxi, China
Jilin Province Tumor Hospital-oncology department ( Site 3126)
Changchun, Jilin, China
Jinan Central Hospital-oncology department ( Site 3122)
Jinan, Shandong, China
Shandong Cancer Hospital ( Site 3119)
Jinan, Shandong, China
Shanghai Changhai Hospital ( Site 3125)
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University ( Site 3124)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 3105)
Chengdu, Sichuan, China
The Second People's Hospital of Neijiang ( Site 3140)
Neijiang, Sichuan, China
Yunnan Province Cancer Hospital ( Site 3139)
Kunming, Yunnan, China
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3111)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province-Respiratory ( Site 3114)
Taizhou, Zhejiang, China
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600)
Bogotá, Bogota D.C., Colombia
IMAT S.A.S ( Site 0602)
Montería, Departamento de Córdoba, Colombia
Oncologos del Occidente ( Site 0603)
Pereira, Risaralda Department, Colombia
Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 1103)
Ostrava, Ostrava Mesto, Czechia
Multiscan-Onkologicke a radiologicke centrum Multiscan Pardubice ( Site 1105)
Pardubice, Pardubický kraj, Czechia
Vseobecna fakultni nemocnice v Praze-Onkologicka klinika ( Site 1106)
Prague, Praha 2, Czechia
Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 1102)
Olomouc, , Czechia
Regionshospitalet Gødstrup-Kræftklinikken ( Site 1204)
Herning, Central Jutland, Denmark
Aalborg Universitetshospital, Syd-Department of Oncology ( Site 1201)
Aalborg, North Denmark, Denmark
Odense Universitetshospital ( Site 1200)
Odense, Region Syddanmark, Denmark
Hôpital Saint Joseph-ONCOLOGY ( Site 1308)
Marseille, Bouches-du-Rhone, France
Institut Régional du Cancer Montpellier-Medical Oncology ( Site 1309)
Montpellier, Herault, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Unité d'oncologie thoracique et cutané ( Site 1303)
Limoges, Limousin, France
Centre d'Oncologie de Gentilly ( Site 1301)
Nancy, Meurthe-et-Moselle, France
Centre Hospitalier de la Côte Basque ( Site 1300)
Bayonne, Pyrenees-Atlantiques, France
L HOPITAL NORD OUEST ( Site 1310)
Gleizé, Rhone, France
Clinique de l'Europe-Service de pneumologie ( Site 1304)
Amiens, Somme, France
Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 1305)
Poitiers, Vienne, France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Medizinische Klinik V ( Site 1409)
München, Bavaria, Germany
Klinikum Bogenhausen-Klinik für Pneumologie und Onkologische Pneumologie ( Site 1406)
München, Bavaria, Germany
Klinikum Nürnberg Nord-5. Med. Klinik ( Site 1407)
Nuremberg, Bavaria, Germany
Universitätsklinikum Marburg-Comprehensive Cancer Center ( Site 1412)
Marburg, Hesse, Germany
Medizinische Hochschule Hannover-Department of Pneumology ( Site 1411)
Hanover, Lower Saxony, Germany
Bethanien Krankenhaus Moers ( Site 1400)
Moers, North Rhine-Westphalia, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus-Medizinische Klinik A ( Site 1410)
Münster, North Rhine-Westphalia, Germany
Universitätsmedizin Johannes Gutenberg Universität Mainz- Klinik für Pneumologie ( Site 1404)
Mainz, Rhineland-Palatinate, Germany
LungenClinic Grosshansdorf-Onkologie ( Site 1401)
Großhansdorf, Schleswig-Holstein, Germany
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1403)
Gera, Thuringia, Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1402)
Berlin, , Germany
Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1804)
Bari, Apulia, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 1807)
Meldola, Emilia-Romagna, Italy
P.O. "S. Maria della Misericordia" Azienda Sanitaria Univers-Oncology Department ( Site 1803)
Udine, Friuli Venezia Giulia, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
Milan, Lombardy, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 1810)
Bergamo, , Italy
AOU Renato Dulbecco ( Site 1801)
Catanzaro, , Italy
Azienda Ospedaliera Universitaria Careggi ( Site 1809)
Florence, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1806)
Roma, , Italy
Fujita Health University Hospital ( Site 3411)
Toyoake, Aichi-ken, Japan
Hirosaki University Hospital ( Site 3429)
Hirosaki, Aomori, Japan
National Cancer Center Hospital East ( Site 3403)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 3415)
Matsuyama, Ehime, Japan
National Hospital Organization Kyushu Cancer Center ( Site 3417)
Fukuoka, Fukuoka, Japan
Kurume University Hospital ( Site 3418)
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center ( Site 3402)
Ōta, Gunma, Japan
National Hospital Organization Himeji Medical Center ( Site 3426)
Himeji, Hyōgo, Japan
Iwate Medical University Hospital ( Site 3428)
Shiwa-gun, Iwate, Japan
St. Marianna University Hospital ( Site 3421)
Kawasaki, Kanagawa, Japan
Yokohama Municipal Citizen's Hospital ( Site 3425)
Yokohama, Kanagawa, Japan
Kanagawa Cancer Center ( Site 3408)
Yokohama, Kanagawa, Japan
Matsusaka Municipal Hospital ( Site 3422)
Matsusaka, Mie-ken, Japan
Tohoku University Hospital ( Site 3424)
Sendai, Miyagi, Japan
Sendai Kousei Hospital ( Site 3400)
Sendai, Miyagi, Japan
Kansai Medical University Hospital ( Site 3412)
Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 3413)
Takatsuki, Osaka, Japan
National Hospital Organization Ureshino Medical Center ( Site 3427)
Ureshino, Saga-ken, Japan
Niigata Cancer Center Hospital ( Site 3409)
Niigata, Saitama, Japan
Shizuoka Cancer Center ( Site 3410)
Suntogun, Shizuoka, Japan
Dokkyo Medical University Hospital ( Site 3401)
Shimotsugagun, Tochigi, Japan
Tokyo Metropolitan Komagome Hospital ( Site 3405)
Bunkyo, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 3404)
Koto, Tokyo, Japan
Toho University Omori Medical Center ( Site 3420)
Ōta-ku, Tokyo, Japan
Tokyo Medical University Hospital ( Site 3407)
Shinjuku, Tokyo, Japan
National Center for Global Health and Medicine ( Site 3406)
Shinjuku, Tokyo, Japan
National Hospital Organization Yamaguchi Ube Medical Center ( Site 3423)
Ube, Yamaguchi, Japan
National Hospital Organization Kyushu Medical Center ( Site 3416)
Fukuoka, , Japan
Saiseikai Kumamoto Hospital ( Site 3419)
Kumamoto, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 3414)
Osaka, , Japan
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0715)
Guadalajara, Jalisco, Mexico
Higiea Oncologia ( Site 0721)
Mexico City, Mexico City, Mexico
Axis Heilsa S. de R.L. de C.V. ( Site 0719)
Monterrey, Nuevo León, Mexico
Centro de Atención e Investigación Cardiovascular del Potosí ( Site 0713)
San Luis Potosí City, San Luis Potosí, Mexico
Oaxaca Site Management Organization S.C. ( Site 0718)
Oaxaca City, , Mexico
Clinica Integral Internacional de Oncología ( Site 0714)
Puebla City, , Mexico
Amphia Ziekenhuis, locatie Breda Molengracht-long oncologie ( Site 1901)
Breda, North Brabant, Netherlands
ETZ Elisabeth-Department of Pulmonary Diseases ( Site 1902)
Tilburg, North Brabant, Netherlands
Isala, locatie Zwolle-Poli Longziekten ( Site 1903)
Zwolle, Overijssel, Netherlands
Clinica Vallesur - AUNA ( Site 0854)
Arequipa, Ariqipa, Peru
Detecta Clínica ( Site 0853)
Surquillo, Muni Metro de Lima, Peru
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 0851)
Lima, , Peru
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0850)
Lima, , Peru
Hospital Cayetano Heredia-Oncology ( Site 0855)
Lima, , Peru
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 2013)
Grudziądz, Kuyavian-Pomeranian Voivodeship, Poland
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 2016)
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 2015)
Krakow, Lesser Poland Voivodeship, Poland
Instytut Gruźlicy i Chorób Płuc w Warszawie-3rd Dep of Lung Diseases and Oncology ( Site 2011)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2001)
Przemyśl, Podkarpackie Voivodeship, Poland
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2018)
Olsztyn, Warmian-Masurian Voivodeship, Poland
SPZOZ Uniwersytecki Szpital Kliniczny Im. Wojskowej Akademii Medycznej UM W Łodzi Centralny Szpital ( Site 2012)
Lodz, Łódź Voivodeship, Poland
Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 2104)
Lisbon, Lisbon District, Portugal
Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 2101)
Lisbon, Lisbon District, Portugal
Hospital Dr. Nélio Mendonça ( Site 2105)
Funchal, Madeira, Portugal
Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 2103)
Vila Nova de Gaia, Porto District, Portugal
Hospital CUF - Tejo ( Site 2100)
Lisbon, , Portugal
Wonju Severance Christian Hospital ( Site 3808)
Wŏnju, Kang-won-do, South Korea
National Cancer Center ( Site 3801)
Goyang-si, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3800)
Suwon, Kyonggi-do, South Korea
Ajou University Hospital-Hematology-Oncology ( Site 3806)
Suwon, Kyonggi-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 3804)
Cheongju-si, North Chungcheong, South Korea
Keimyung University Dongsan Hospital CRC room 1 ( Site 3807)
Daegu, Taegu-Kwangyokshi, South Korea
Asan Medical Center-Lung Cancer Center ( Site 3805)
Seoul, , South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 3802)
Seoul, , South Korea
Hospital Jerez de la Frontera-UGC Oncología ( Site 2333)
Jerez de la Frontera, Cadiz, Spain
CHUAC-Hospital Teresa Herrera-MEDICAL ONCOLOGY ( Site 2335)
A Coruña, La Coruna, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2331)
Pozuelo de Alarcón, Madrid, Spain
H.R.U Malaga - Hospital General ( Site 2332)
Málaga, Malaga, Spain
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2336)
Valencia, Valenciana, Comunitat, Spain
Hospital Universitari Vall d'Hebron-Oncology ( Site 2330)
Barcelona, , Spain
Hospital La Princesa ( Site 2338)
Madrid, , Spain
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 2337)
Seville, , Spain
Chi Mei Hospital - Liouying Branch ( Site 3908)
Tainan, Tainan, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 3907)
Taipei City, Taipei, Taiwan
National Taiwan University Hospital - Hsinchu branch ( Site 3901)
Hsinchu, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3904)
Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital at Kaohsiung ( Site 3902)
Kaohsiung City, , Taiwan
Taipei Medical University Shuang Ho Hospital ( Site 3912)
New Taipei City, , Taiwan
Taichung Veterans General Hospital-Chest ( Site 3905)
Taichung, , Taiwan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 3903)
Tainan, , Taiwan
Chi Mei Medical Center ( Site 3915)
Tainan, , Taiwan
National Taiwan University Hospital-Oncology ( Site 3906)
Taipei, , Taiwan
Mackay Memorial Hospital ( Site 3909)
Taipei, , Taiwan
Chulalongkorn University-Medicine ( Site 4003)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 4000)
Bangkok, Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital-Chiang Mai Clinical Trial Unit (CM-CTU) ( Site 4001)
Chiang Mai, , Thailand
Medipol Mega Universite Hastanesi-oncology ( Site 2508)
Stanbul, Istanbul, Turkey (Türkiye)
Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2503)
Bornova, İzmir, Turkey (Türkiye)
Erciyes University ( Site 2511)
Talas, Kayseri, Turkey (Türkiye)
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2507)
Adana, , Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi-oncology ( Site 2506)
Ankara, , Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2501)
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 2505)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi ( Site 2500)
Ankara, , Turkey (Türkiye)
Pamukkale University Medical Faculty, Fahri Goksin Oncology Centre-Oncolgyy-Hematology ( Site 2510)
Denizli, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502)
Istanbul, , Turkey (Türkiye)
Ondokuz Mayıs Universitesi ( Site 2509)
Samsun, , Turkey (Türkiye)
Royal Free Hospital ( Site 2601)
London, England, United Kingdom
Queen Alexandra Hospital-Oncology Department ( Site 2603)
Portsmouth, Hampshire, United Kingdom
Kent and Canterbury Hospital-Oncology Research ( Site 2606)
Canterbury, Kent, United Kingdom
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 2605)
London, London, City of, United Kingdom
James Cook University Hospital ( Site 2604)
Central Middlesbrough, Middlesbrough, United Kingdom
National Lung Hospital-Oncology Department ( Site 4175)
Hanoi, Hanoi, Vietnam
Tam Anh General Hospital ( Site 4179)
Hanoi, Hanoi, Vietnam
Cho Ray Hospital ( Site 4171)
Ho Chi Minh, Hanoi, Vietnam
K Hospital - National Cancer Hospital ( Site 4174)
Hà Nội, , Vietnam
Ho Chi Minh City Oncology Hospital - Tan Phu Ward ( Site 4173)
Ho Chi Minh City, , Vietnam
Thong Nhat Hospital ( Site 4170)
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-2870-007
Identifier Type: OTHER
Identifier Source: secondary_id
2023-503376-24-00
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2051240089
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1287-1395
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.